Good afternoon, and welcome to the Agile Therapeutics fourth quarter and full year 2021 financial results conference call. After today's presentation, there will be a question-and-answer session. To ask a question, press star and the number one on your telephone. Please note today's event is being recorded. I would now like to turn the conference over to Matt Riley, Head of Investor Relations. Hello, everyone, and welcome to today's conference call to discuss our fourth quarter and full year 2021 financial results and corporate update. Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, our outlook for the first quarter of 2022, management's expectations for our future financial and operational performance, our business strategy, and our assessment of the combined hormonal contraceptive market, among other statements regarding our plans, prospects, and expectations. Such statements represent our judgments as of today, are not promises or guarantees, and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Please refer to our filings with the SEC, which are available through the investor relations section of our website, for information concerning risk factors that may affect the company. We undertake no obligation to update forward-looking statements except as required by law. The information on today's call is not intended for promotional purposes and not sufficient for prescribing decisions. Joining me on today's call are Al Altomari, Agile Therapeutics Chairman and Chief Executive Officer, and Dennis Reilly, Chief Financial Officer. Following our prepared remarks, we'll open the call to your questions. I will now turn the call over to Dennis. Thank you, Matt, and thank you all for joining us on our call this afternoon. I will review the key areas of our financial performance for fourth quarter and full year 2021, and then discuss our cash position and plan to finance the company. I will then hand the call over to Al for an update on our business plan for 2022. Overall, 2021 was our first full year of commercialization, and we saw steady growth in TWIRLA across a number of metrics in both demand and revenue as we have sought to establish TWIRLA in the market. Beginning with revenue, we realized net product sales revenue of $1.5 billion in the fourth quarter as compared to $1.3 million in the third quarter of 2021. Our net revenue for the fourth quarter was at the high end of the range we guided in January and brings us to $4.1 million in revenue for the full year 2021. Our cost of product revenue for Q4 2021 was $5.7 million, which included a $4.5 million inventory obsolescence charge for product not expected to be sold prior to its shelf life date, which is 12 months prior to expiry. Full year cost of product revenue was $10.7 million, including $5.9 million of inventory obsolescence reserves. While we believe we have managed our inventory down to a level that more closely tracks to demand, we will continue to closely monitor this area and take the appropriate steps when necessary. Our operating expenses were $18.2 million in Q4 2021 versus $17.2 million in the same period a year ago. Again, we're within our guidance of $17.5 million-$19.5 million communicated in January. Full year operating expenses were $64.4 million compared to $49.5 million in 2020. The overall increase is primarily related to our spend in support of building and promoting our TWIRLA brand in order to establish it in the marketplace through our direct-to-consumer or DTC marketing and our sales force, which was in place for the full year of 2021. We remain focused on maintaining our disciplined spending approach and making the right investments to encourage strategic growth while implementing what we believe to be impactful partnerships and agreements. Al will provide more detail on our 2022 business plan in a moment. We anticipate our quarterly spending for the first quarter of 2022 to decrease slightly and to be in the range of $16 million-$18 million while maintaining spend on product sample batches and brand marketing. This reflects our plan to reduce spending in other parts of our operations in order to maximize and focus our investments in the DTC campaign that Al will describe. We closed out the fourth quarter 2021 with a net loss of $23.4 million or $0.20 per share, compared to the net loss of $17.6 million or $0.20 per share for the comparable period in 2020. The full year net loss was $74.9 million or $0.77 per share for 2021, compared to $51.9 million or $0.61 per share in 2020. At December 31st, 2021, we had cash equivalents of $19.1 million as compared to $14.7 million of cash and cash equivalents at the end of the third quarter of 2021. This increase on hand related to a public offering completed in the fourth quarter, netting $21.1 million, offset by our working capital burn during the quarter. Financing update. We continue to explore financing options to support the growth of TWIRLA. Our plan to finance the company is focused on three parts. One, working down our debt facility with Perceptive Advisors. Two, regaining compliance with the NASDAQ listing requirements. Three, raising additional capital. We currently have no plans to further leverage the company and therefore will not add additional funds under our debt facility. In January 2022, we retired $5 million in debt from Perceptive Advisors, reducing our debt to $15 million in exchange for relief on certain of our financial covenants. In the second quarter, we plan to make another payment of $5 million in principal in exchange for further relief. In March 2022, we closed a $4.85 million registered direct offering of preferred stock with a single healthcare-focused institutional investor. In addition, we anticipate an additional $4.7 million in funding in the coming weeks from the sale of New Jersey net operating losses. As we have previously reported, we were notified by NASDAQ that we are out of compliance with their minimum bid requirement, which requires our stock to trade consistently over $1, and that we have until May 9th, 2022, to regain compliance. While we might be able to secure an additional six months to regain compliance, we are working to regain compliance by NASDAQ's original target date. We believe that increasing the price of our common stock at this time would allow us to regain compliance with NASDAQ and better position us for further fundraising, thereby helping to de-risk the company. To that purpose, we have called a special meeting of stockholders on April 21st, 2022, to seek approval for a reverse stock split. We will require additional capital to achieve our goal of being cash flow positive. We anticipate that as our sales growth continues to gather momentum, our optics on revenue will become clearer and allow us to better define the path and timeline to positive cash flow. We will continue to evaluate all options available to us to finance the company, including further equity offerings and various business development and partnership opportunities to accelerate our path to profitability. We believe we ended 2021 with momentum behind TWIRLA and a focused, targeted plan to build on that momentum in 2022, which Al will now describe for you. Al, over to you. Great. Thank you, Dennis, and thank you, Matt. Thank you everyone for joining us today and continuing to follow our story at Agile. Dennis referenced our belief that in 2021, we began to build momentum for TWIRLA. I want to spend my time today providing further context and highlighting our plan to build on that progress throughout 2022. In the first half of 2021, we laid the foundation for TWIRLA by deploying our sales force and sampling program to create awareness with healthcare providers. Beginning in the third quarter of 2021, we started to see consistent and meaningful demand growth. From the end of the third quarter to the end of the fourth quarter in 2021, we saw the following. Total cycles dispensed grew 35% to 12,849. Total prescriptions or TRxs grew 33% to 9,837. New prescriptions or NRxs grew 22% to 4,381. Refills grew 47% to 5,456. Total prescribers grew 40% to 4,640 prescribers. Another quarter of double-digit growth is encouraging, and we believe there are many signs of a healthy, growing brand, for instance, the level of refills. Now our objective is to continue this trend into 2022 by executing on our business plan. We believe we designed a plan that could allow us to continue to build on the steam and the TWIRLA growth while assuming no changing in the reimbursement or Affordable Care Act arena. We believe that any positive changes in reimbursement and the ACA could have potential upside on the growth for TWIRLA in 2022. This plan has three primary components that we think will contribute to reaching our objectives. First, our partnership with Afaxys. In January 2022, we launched our co-promotion partnership with Afaxys through their group purchasing organization, which primarily provides services to the non-retail channel. Afaxys has the potential to access to over 25,000 accounts, including colleges and university student health centers and Planned Parenthoods. We have previously stated that access to Planned Parenthood was a priority for Agile and TWIRLA, and we believe the partnership with Afaxys gets us there in an efficient, targeted way. The growth graph we just showed and have shown to date reflects the traditional retail channel only. Generally, retail sales are units dispensed to the end user at pharmacy or through mail order telemedicine, and non-retail sales are units sold or dispensed to public health clinics or institutions. In the second quarter of 2021, a single state purchased 2,200 non-retail units, which showed us the potential impact that this non-retail channel can have on our business. We believe that Afaxys and its sales force can deliver on the non-retail growth, and we expect to see contributions from that channel ramp throughout 2022. The second component of our business plan is to focus on California, the largest U.S. market for contraceptives, through the preferred position on Medi-Cal formulary. On last quarter's call, we announced that Medi-Cal, the largest Medicaid program in the United States, added TWIRLA to the preferred drug list. As of October 1st, 2021, the preferred drug placements for Medi-Cal apply to those beneficiaries who receive their pharmacy benefits through the fee-for-service plans and related programs with the remainder of the beneficiaries gaining access as of January 1st, 2022. This is significant for Agile and TWIRLA because Medi-Cal provides health care to approximately 15 million beneficiaries, and 1/3 of the existing patch market comes from Medicaid. Because TWIRLA is now active on the Medi-Cal formulary, driving TWIRLA awareness and adoption in California is a priority, which leads us to the third component of our business plan. We are excited to announce a brand new TWIRLA direct-to-consumer commercial that will air on connected TV, also known as CTV, and is set to launch in early April. The tagline for this commercial is "Patch and Play." The objective of this spot is simple: We want patients to ask their doctors about TWIRLA. For those of you who are unfamiliar with CTV, it refers to the internet-connected video streaming across smart TVs, desktops, mobile, and tablet, which just allows us to buy exposure to a specific target viewers wherever they are watching streaming content, rather than buying space on particular TV shows or networks. We are deploying the commercial with a highly targeted, efficient focus on women in our target age demographic, 18 to 24, in the big five states of California, Texas, Florida, Illinois, and New York. These states have large markets for contraception and potentially strong commercial coverage for TWIRLA. By targeting these five states, we believe we're able to reach between 41% and 45% of our key customer base in this country, or approximately 5.7 million women, ages 18-24. For those of you interested in viewing the ad who aren't an 18- to 24-year-old woman, it will be made available on TWIRLA's YouTube channel and in the future on agiletherapeutics.com. We've been adamant that traditional cable TV is an inefficient mass advertising approach that does not land directly on our target TWIRLA's audience. Moreover, we believe cable TV is an expensive strategy and is currently not a responsible way to utilize our valuable consumer marketing dollars. We think CTV is a highly targeted and cost-effective way for us to re-reach nearly half of our target market. CTV is the next phase of our DTC approach to increase TWIRLA awareness and encourage TWIRLA adoption. This complements the digital DTC programs we announced on the third quarter call of 2021, and it's worth noting we are seeing territories where there are no TWIRLA sales representatives producing prescriptions. We believe this signals that current DTC efforts are gaining traction and producing results. This is the plan we have in place for 2022, and our focus is on building upon the momentum we established throughout 2021. The Afaxys partnership and new Medi-Cal program developments have effectively come online in January 2022, and we expect that the contribution to our growth to ramp well into 2022. The TWIRLA CTV commercial will air early in April 2022, and we believe will contribute to the demand growth we're seeing. Even without these components being fully deployed in the first quarter, we saw the brand momentum continue, as you will see on the graph here that shows the four-week rolling average for the fourth quarter of 2021 and the first quarter of 2022. This is why we have confidence that as our key initiatives for 2022 begin to contribute to our overall results, our business plan can be successful. Before we begin the Q&A, I wanna touch on the federal activity surrounding the enforcement of the Affordable Care Act or the ACA. We believe the high interest level regarding contraceptive access and the implementation of the ACA requirements across advocacy groups, members of Congress and the Senate, Congressional and Senate committee chairs is an effort to support a basic sound policy. Women and their providers are the best determinants of contraceptive care. As a result of that interest, in January 2022, U.S. Departments of Labor, Health and Human Services, and Treasury updated guidelines reinforcing the requirements for most commercial insurers and their PBMs to cover all FDA-approved contraceptives at no cost if deemed medically necessary by their provider. They specifically indicated that the plans may not require patients to try and fail multiple options or require patients to try methods other than the one recommended. In addition, Health Resources and Services Administration, or also known as HRSA, updated their women's preventive service guideline for plan years beginning in 2023 to include coverage of all FDA-approved, granted or cleared contraceptives be made available as part of contraceptive care. These updated guidelines are potentially significant. We will continue to engage with plans as they begin to evaluate their practices to comply with the ACA requirements. We will continue to monitor developments in this area very closely. We think we have a well-designed plan for 2022, and if we continue to execute consistently, we can achieve meaningful progress in building our business in 2022. We'd like to give a chance for our covering analysts to take this opportunity to ask any questions. Operator, you may now open the line for Q&A. Ladies and gentlemen, just as a reminder, if you'd like to ask a question, please press star and the number one on your telephone keypad. Once again, that is star and the number one. Your first question comes from the line of Leland Gershell. Hi. Congratulations on the progress. Thanks for taking my question. Couple questions. First, just, you know, as you expand the DTC campaign, just want to ask if you have any metrics or kind of feedback on the effectiveness on the different aspects, you know, of your DTC initiatives. Also, with respect to the enforcement under the ACA, just want to ask if you've seen, you know, any tangible signs of either enforcement or threat of enforcement, how that may have positively impacted TWIRLA at this point. Thank you. Yeah. Thanks, Leland. Let's do them in order. Your first question about metrics or signs of DTC. You know, we're pretty excited about what we're seeing so far. You know, I mentioned in my talk that you know, clearly DTC works better when we have a sales representative in front of a doctor while we're deploying DTC. It's clear that that's you know, the best outcome. We have kind of a Leland, kind of an experiment we look at where we said, "Well, where don't we have sales representatives?" We have zip codes and in some cases states where we don't have sales representatives that we said, "Well, let's deploy DTC and see if we can move the needle." We can. We know DTC is strong enough to work on its own. We know it's better when it works you know, in parallel with our sales force. That's an important metric for us. It gave us confidence to say, "Okay, let's take it to the next level." Because our DTC has generally been, you know, Amy Welsh, our head of marketing, you know, I'm not sure she would agree if I call it print advertising, but it's print. It's flat media. It's for the most part digital, you know, print. It's worked really hard. We think we can take it to the next level, and that's why we're excited about the CTV. It's a video. We don't wanna call it a commercial, but it's a video. Hopefully, you'll get not only a good laugh at it, you know, because we, you know, it shows women interacting with other women. Because we know that the number one, and if you will, advocate for a brand is a woman's, uh, girlfriends. You know, that's why we do the influencer programs we do. We wanna take advantage of that dynamic. Then the other metric we look at, just to complete the answer to you, is we look at when we run media, do we light up our websites and, you know, do we get, you know, traffic? And we do. We see a pretty quick response. We know it works. You know, we know it can work harder. What we wanna do is, you know, be smart with it, as I mentioned in the talk. Because we know we're throwing a DTC into some states where we don't have great coverage or we don't have enough of a sales footprint. We said, "Why don't we deploy our spending? Let's go heavier in areas that the pump's already primed, if you will." With the sales force footprint, you know, reimbursement coverage and, you know, obviously, you know, high density. That's why we picked the big five. You know, that's what we look at, Leland, to kind of get to the next level. The second question you asked is about the ACA. You know, I wish I could tell you that, you know, we're seeing a lot of changes in behavior. We're seeing a lot of interest, a lot of activity. We've gotten inbound calls, you know, about our coverage. I think the issue has come at least to the forefront, you know, of the insurance company, the PBMs mind. You know, but now it's got to get to the next level. We've got to change behavior. We're starting to see that, you know, work a little bit better, you know, so we get a better conversion of our scripts. You know, I don't think it's a coincidence that we had our best month ever. You know, I'll put my neck on the line a little bit. You know, we saw the highest growth we've seen, you know, in this brand in March, and it's not quite over yet. We see so we think the market's evolving, Leland, you know, probably not as fast as I want. We said, "Let's just develop a business plan that says status quo." We've got to play the cards we're dealt, and that's what we're doing. We're just, you know, I hope that I could say to you at the end of the first quarter that we put up three monster quarters in a row where we've grown our top units well over 30%. To keep compounding 30% on 30% on 30% on the cycles going out the back door, you know, is just, I think, a great testimony to the brand and to the people in our company. You know, we're optimistic, and we just see it as an upside, Leland. You know, we think based on these guidelines from HRSA, you know, and then, you know, we think that what's going on in D.C. and the awareness. We still think our better days are ahead of us, but doesn't mean it's gloom and doom right now. We're motoring right now. You know, we've officially dropped the flag and said we've got momentum on this brand. We don't see growth. We see real momentum now. We're pleased. We wanna do more. I think these initiatives we did, you know, hopefully, you know, accelerate that. For right now, we're pleased. You know, on the ACA side, Leland, scripts go through a little bit easier. We're seeing some upside. You know, we think there's less friction, if you will, in the marketplace, but not enough just yet. We think it's an evolving story. You know, we're ready. You know, we'll keep working hard and with the cards we're dealt. You know, in the meantime, we see it as a big upside for later in 2022 and then hopefully into 2023. If you like the 30%-35% growth, let that get cleaned up and we'll really rock. Sorry, yeah, two really important questions. No, not at all. Very helpful. Thanks so much, Al. Thanks. Your next question comes from the line of Oren Livnat with H.C. Wainwright. Hi, guys. Thanks for taking the questions. Yeah, it's a nice growth curve you got going. I hope you can keep it up. Regarding these, I guess, key focus areas for 2022 in terms of, you know, the most exciting growth opportunities you've called out being Medi-Cal and the Afaxys. I was just hoping, you know, if possible, you can just help me better understand, I guess sort of the size of those pies potentially. I think you said that 1/3 of all patches go through Medicaid. I guess that's overall Medicaid. Are you able to give us a sense of what sort of, you know, CHC volume, prescription volume, patch, maybe specific volume goes through Medi-Cal specifically? And on the Afaxys front, I guess, you know, I don't really have a great... I mean, I know it doesn't show up on IQVIA, right? That's a volume I can't track. Are you able to give us any sense of sort of how big the volume of their overall, you know, contraceptive portfolio business is? You know, just so we can have a sense of what kind of scale potential even exists within those channels. I have a follow-up or two. Super questions, Oren. Let's talk about Medi-Cal first. You know, California is roughly in line with the nation. In general, about a third of the contraceptive patch volume in this country currently runs through the Medicaid books. We see that in California. You know, I don't have the exact numbers in front of me. It's a huge potential market for us through that Medicaid book. It's meaningful. It can move the national needle itself. What's exciting for me is that, you know, generally you put reps in front of doctors and you say, well, it takes multiple times to kind of get doctors the right product, Oren. Like, the first week of January, we sold scripts in California, not many, but we sold California scripts, and it's growing at a pretty nice clip. I think of market share sometimes. Our market share in Medi-Cal in California might be at or beyond the national market share we have. You know, we're already doing as well in Medi-Cal, I'm sorry, after two months that took us the better part of 2021. That shows you how excited the doctors are in California. You know, I wish I had off the top of my head, you know, the size of the market. Patches are a big piece of business there. It's a significant amount of volume in California. It's meaningful. It'll move the national needle. The other thing with Afaxys, you know, they have their own brands, so they have a lot of, you know, generic pills they sell. They have their own products. They obviously don't have a patch, and they don't have other forms of contraception like the ring. They kind of work with partners to complete their offering, if you will. You know, and you're right, their volume in Medicaid generally, the Planned Parenthood volumes don't run through IQVIA or Symphony. You get the data for these. Generally, everything runs through there, but these don't. They don't report to IQVIA, and a lot of student health centers don't either. I mean, nationally, we think it's hundreds of thousands of potential cycles up for grabs in patch volume, hundreds of thousands. We'd like to take a piece of that pie, right? If we take a reasonable slice of that pie, you know, based on what I just reported, you know, like in the quarter, let's do it, you know. We were proud of the 12,000 cycles we did in the fourth quarter. You know, that's less than 4% or 5% of, you know, of Afaxys' patch volume. Imagine I can get a decent slice of your Afaxys business, Oren. It's meaningful. If there's hundreds of thousands of, you know, patch volumes, you know, that's up for grabs in Afaxys' current book, and we think we wanna get a piece of it. That's gonna take us some time. You know, these are contracts. It's not like you walk into a doctor's office, and they write a script for you. This takes us time to get under contract and, you know, they have to purchase through the GPO. You know, we're starting to see a smidgen, you know, small amount, not very meaningful show up in the first couple weeks they've been in business. We think this is gonna build over time, and we think probably in the next couple quarters, more than likely the second or third, it'll be more meaningful that we might report it separately to you. For right now, we're just starting to lay the groundwork for that. I think Afaxys is gonna contribute more, I think, to the top line of Agile, I'd say in the second half of the year. I think Medi-Cal will start paying, you know, getting some scripts. It's already getting now, and we expect that's already contributing. You know, I think that's why our March data is starting to light up. That's why. Thank you for the comment about the curve. We like March a lot. We like to think that if you tease out March, it really looks good, you know, 'cause we're having a really great March. We'd like to see that continue, obviously. Thank you for noticing it. It's important to us, and I think that's, you know, we wanna keep going. All right. If I may, just, you know, you talk about targeting 18-24-year-olds, and, you also mentioned, you know, taking patch share. I'm not sure these are, you know, the same pools of patients. I just wanna understand your targeting and how you've sort of chosen, you know. Obviously, the oral contraceptive market is, you know, the vast majority of the overall volume and switches from there or new starts, you know, represents a bigger potential pie overall for you long- term. Is that why you're targeting younger patients just 'cause they're earlier- Yeah. -on the journey? or- Yeah. Is there some other profile that you're targeting? No, I think you answered your own question. I mean, I think Okay. In general, I think we mentioned before that about 50% of our business comes from a woman, you know, who probably more than likely is this is her first step on the journey or maybe she's been on pills before. Roughly 75%-80% of our business comes either from a new start or somebody's been on pills. We think she's relatively early in her journey, as we probably all know, is that women can start before 18 and oftentimes do. We think that the 18-24 kinda is that sweet spot where she's more than likely she's either tried a pill or more than likely hasn't been that happy with a pill and is looking for something different, and isn't ready to sign up for, you know, tubal ligation or a ring or potentially an IUD. We think it's a sweet spot. It also happens to be, Oren, like there's some science to buying media. It actually is a real clean media buy, too. We think they're very engaged with their media, so we think they're very responsive. At that point, they're making a lot of decisions for themselves about which brands they go on. We think it's a really smart buy of media, but we also think it lines up with what we're seeing in, you know, who's using our product right now. Then you're right. There's, you know, a case to be made, we should go a little older and maybe a little younger, but we gotta walk before we run a little bit. We'll put our media where we think we get the best bang for the buck. Okay. If I may, I appreciate you're not hiding from the liquidity situation. You know, obviously tough launching a single drug as a small company, and you're not the only one, even in the women's health business that is facing those challenges. Just strategically, given there are several companies in this space in similar situations, how much thought do you lend to strategic alternatives, whether it's merge, buying, selling in some way to get some leverage in this space, so that they could where one plus one equals three? Yeah, I mean, it's probably, you know, sort of running our business, it's the second thought that hits my mind. I think all of us that have a one product company with a point of sales force should look for ways to make that more efficient. You know, we are really open to, you know, collaborating with other women's healthcare companies. We're open to finding another if we could find another product for our bag, if we can help somebody out. I think, you know, I think we all should be looking for ways to leverage our infrastructure costs. I think it's a really important effort that we take really serious. You know, we're in a lot of conversations. We try real hard. You know, obviously, we don't have anything to show you, but I think it is top of mind for me. I do. I think if there's two things, if we can get another product in our bag, it makes our math clearly a lot better. Also, I leave a lot of open gaps on the map. You know, there's only so many sales reps that we can afford. We put them where we think the best bang for our buck. If somebody wants to put our product in their bag and can do it more efficiently than us, we're open for that, too. Based on what your comments about the capital markets are, you know, we all should be thinking that, Oren, so it's certainly top of mind. Unfortunately, it's a relatively small space. There's just not a ton of opportunities. We all, you know, it's just we don't have 50 choices, if you will. We've got to work harder at it. You know, we're in good conversations, but for right now, you know, that's all I can tell you, that I'm just being straight. All right. Well, thanks for accommodating all the questions. Now I'd like to turn the call over to Al Altomari for any closing remarks. No, thank you, operator. Thank you, Matt and Dennis, for your help. Dennis described that we're trying to, and Oren just touched on it, look at our managing our quarterly operating expenses and working to regain compliance with NASDAQ. We have to finance the company. We wanna lay out our plans as Dennis did, and let you know exactly what's in our minds. We think we're using our marketing spend in a very wise way, focusing on large markets with potential good coverage return or strong commercial coverage. In summary, we believe this brand is demonstrating steady growth and steady momentum. It's beyond, it's now predictable. It's not a surprise that we had one or two good quarters. We've now strung together three quarters, hopefully going into the first quarter of strong growth. We think our business plan, you know, that we're working with is designed to help TWIRLA even grow more in 2022. In the meantime, you know, you can keep an eye out for the CTV ad we mentioned. You know, we'll put out an announcement, you know, shortly about it. Also, I wanna let you know that, you know, the company's gone to a very major conference. It's the American College of Obstetrics and Gynecology, or called ACOG. It's in May, so we're gonna have a strong footprint there, both on the commercial side and also on the scientific side. More to come there. Anybody in, you know, would like to know more about that, we'll be putting out some information about that. I think the other thing I wanna mention about ACOG that I think it's important for you to know is that sometimes you just get lucky. ACOG this year and our key market, ACOG is in California, in San Diego. We, you know, we're thrilled to put our major presence out and our, you know, foot forward in the California market at such a critical time. Thank you for joining us, and you know, we look forward to updating you know, as we go through 2022. Thanks for following our story, and thanks for your interest in the company. We appreciate it. Ladies and gentlemen, this concludes today's conference call. We thank you for your participation. You may now disconnect.